MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer
MacroGenics reported positive interim Phase 2 LINNET data for lorigerlimab, a bispecific PD-1/CTLA-4 DART molecule, in advanced clear cell gynecologic cancer, presented at the ESMO 2026 Congress. Among 16 response-evaluable CCGC patients, confirmed ORR was 25% (4/16) with a 44% disease control rate and all responses ongoing at the September 1, 2026 cutoff; median PFS was 2.9 months. Safety was manageable but meaningful: Grade ≥3 treatment-related adverse events occurred in 49% of all 41 patients, one Grade 5 TRAE in the PROC cohort, and 24% discontinued due to TRAEs.
Key figures
- Drug Name
- lorigerlimab
- Phase Of Trial
- Phase 2
- Dcr ccgc
- 44%
- Orr ccgc
- 25%
- Pfs rate 6mo
- 33%
- Grade3plus trae
- 49%
- Median pfs ccgc
- 2.9 months (95% CI 1.9-6.2)
- Patients treated
- 41
- Trae discontinuation
- 24% overall, 18% in CCGC patients
- Response evaluable ccgc
- 16
- Additional ccgc enrollment
- 20 patients at 3 mg/kg Q3W
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.